董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Frank Fischer | 男 | Chairman of the Board | 83 | 40.89万美元 | 未持股 | 2025-06-24 |
| Rakhi Kumar | 女 | Independent Director | 46 | 未披露 | 未持股 | 2025-06-24 |
| Renee Ryan | 女 | Independent Director | 57 | 0.05万美元 | 未持股 | 2025-06-24 |
| Joel Becker | -- | Director, President and Chief Executive Officer | -- | 未披露 | 未持股 | 2025-06-24 |
| Richard Scott Huennekens | -- | Director | -- | 未披露 | 未持股 | 2025-06-24 |
| Lisa Andrade | -- | Independent Director | -- | 未披露 | 未持股 | 2025-06-24 |
| Uri Geiger | -- | Independent Director | -- | 未披露 | 未持股 | 2025-06-24 |
| Joseph Lacob | 男 | Independent Director | 69 | 未披露 | 未持股 | 2025-06-24 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Martha Morrell | -- | Chief Medical Officer | 69 | 48.40万美元 | 未持股 | 2025-06-24 |
| Joel Becker | -- | Director, President and Chief Executive Officer | -- | 未披露 | 未持股 | 2025-06-24 |
| Patrick F. Williams | -- | Chief Financial Officer | -- | 未披露 | 未持股 | 2025-06-24 |
董事简历
中英对照 | 中文 | 英文- Frank Fischer
-
Frank Fischer，2012年10月起，担任本公司董事。他于2000年加入NeuroPace, Inc，这是神经系统疾病治疗设备的私营开发商，现为其总裁、首席执行官。1998年5月至1999年9月，他担任Heartport, Inc的总裁、首席执行官、董事，这是原心脏外科上市公司，在2001年被Johnson & Johnson收购。1987-1997，他担任Ventritex, Inc的总裁、首席执行官，这是一家上市公司，从事设计、开发、制造、销售用于治疗室性心动过速、心室颤动的植入式除颤器及相关产品，在1997年被St. Jude Medical收购。他目前是一些私营企业的董事。他在Rensselaer Polytechnic Institute获得机械工程学士学位、管理学硕士学位。
Frank Fischer,has more than 40 years of senior management experience in the medical device industry. He co-founded NeuroPace in December 1997, led the company as its President and Chief Executive Officer from January 2000 through July 2019, served on its Board of Directors since inception and is currently Chairman of the Board. Prior to joining NeuroPace, Mr. Fischer was President and Chief Executive Officer of Heartport, Inc., a cardiac surgery company, from May 1998 until September 1999 and served on Heartport's Board of Directors. Previously, Mr. Fischer was President and Chief Executive Officer and a director of Ventritex, Inc., a company that pioneered implantable cardiac defibrillators, from July 1987 until the sale of the company to St. Jude Medical, Inc. in 1997. Before joining Ventritex, he held various management positions at Cordis Corporation from 1977 to 1987 in the cardiac and neurosurgical device areas, serving most recently as President of the Implantable Products Division. Currently he is a member of the Board of Directors of Nevro, Inc., the Board of Trustees of both Rensselaer Polytechnic Institute and Babson College as well as the Board of Directors of the Epilepsy Foundation of America. Mr. Fischer holds B.S.M.E. and M.S. in Management degrees from Rensselaer Polytechnic Institute. - Frank Fischer，2012年10月起，担任本公司董事。他于2000年加入NeuroPace, Inc，这是神经系统疾病治疗设备的私营开发商，现为其总裁、首席执行官。1998年5月至1999年9月，他担任Heartport, Inc的总裁、首席执行官、董事，这是原心脏外科上市公司，在2001年被Johnson & Johnson收购。1987-1997，他担任Ventritex, Inc的总裁、首席执行官，这是一家上市公司，从事设计、开发、制造、销售用于治疗室性心动过速、心室颤动的植入式除颤器及相关产品，在1997年被St. Jude Medical收购。他目前是一些私营企业的董事。他在Rensselaer Polytechnic Institute获得机械工程学士学位、管理学硕士学位。
- Frank Fischer,has more than 40 years of senior management experience in the medical device industry. He co-founded NeuroPace in December 1997, led the company as its President and Chief Executive Officer from January 2000 through July 2019, served on its Board of Directors since inception and is currently Chairman of the Board. Prior to joining NeuroPace, Mr. Fischer was President and Chief Executive Officer of Heartport, Inc., a cardiac surgery company, from May 1998 until September 1999 and served on Heartport's Board of Directors. Previously, Mr. Fischer was President and Chief Executive Officer and a director of Ventritex, Inc., a company that pioneered implantable cardiac defibrillators, from July 1987 until the sale of the company to St. Jude Medical, Inc. in 1997. Before joining Ventritex, he held various management positions at Cordis Corporation from 1977 to 1987 in the cardiac and neurosurgical device areas, serving most recently as President of the Implantable Products Division. Currently he is a member of the Board of Directors of Nevro, Inc., the Board of Trustees of both Rensselaer Polytechnic Institute and Babson College as well as the Board of Directors of the Epilepsy Foundation of America. Mr. Fischer holds B.S.M.E. and M.S. in Management degrees from Rensselaer Polytechnic Institute.
- Rakhi Kumar
-
Rakhi Kumar于2021年4月被任命为我们的董事会成员，在本招股说明书所包含的注册声明生效之前立即生效。自2018年6月以来，Kumar女士一直担任生物制药公司Roivant Sciences的首席会计官，领导Roivant的会计和财务运营以及相关的内部控制职能。Kumar女士于2015年9月加入Roivant，此前曾于2016年12月至2018年6月担任Vice President，财务和外部报告，并于2015年9月至2016年12月担任高级总监。在加入Roivant之前，Kumar女士于2013年6月至2015年9月在The Medicines Company任职，负责外部报告以及公司和技术会计。在职业生涯早期，Kumar女士在安永会计师事务所（Ernst and Young）的保证服务部门任职。Kumar女士在哈特福德大学（University of Hartford）获得会计与税务硕士学位。她是一名注册会计师。
Rakhi Kumar was appointed as a member of board of directors in April 2021 effective immediately prior to the effectiveness of the registration statement of which this prospectus is a part. Since June 2018 Ms. Kumar has served as Chief Accounting Officer at Roivant Sciences, a biopharmaceutical company, where she leads Roivant's accounting and financial operations and related internal controls functions. Ms. Kumar joined Roivant in September 2015 previously serving as Vice President, Finance and External Reporting, from December 2016 to June 2018 and as Senior Director, from September 2015 to December 2016. Prior to joining Roivant, Ms. Kumar was with The Medicines Company, from June 2013 to September 2015 where she was responsible for external reporting and corporate and technical accounting. Earlier in her career, Ms. Kumar was in the assurance services at Ernst and Young. Ms. Kumar earned an M.S in Accounting and Taxation from the University of Hartford. She is a certified public accountant. - Rakhi Kumar于2021年4月被任命为我们的董事会成员，在本招股说明书所包含的注册声明生效之前立即生效。自2018年6月以来，Kumar女士一直担任生物制药公司Roivant Sciences的首席会计官，领导Roivant的会计和财务运营以及相关的内部控制职能。Kumar女士于2015年9月加入Roivant，此前曾于2016年12月至2018年6月担任Vice President，财务和外部报告，并于2015年9月至2016年12月担任高级总监。在加入Roivant之前，Kumar女士于2013年6月至2015年9月在The Medicines Company任职，负责外部报告以及公司和技术会计。在职业生涯早期，Kumar女士在安永会计师事务所（Ernst and Young）的保证服务部门任职。Kumar女士在哈特福德大学（University of Hartford）获得会计与税务硕士学位。她是一名注册会计师。
- Rakhi Kumar was appointed as a member of board of directors in April 2021 effective immediately prior to the effectiveness of the registration statement of which this prospectus is a part. Since June 2018 Ms. Kumar has served as Chief Accounting Officer at Roivant Sciences, a biopharmaceutical company, where she leads Roivant's accounting and financial operations and related internal controls functions. Ms. Kumar joined Roivant in September 2015 previously serving as Vice President, Finance and External Reporting, from December 2016 to June 2018 and as Senior Director, from September 2015 to December 2016. Prior to joining Roivant, Ms. Kumar was with The Medicines Company, from June 2013 to September 2015 where she was responsible for external reporting and corporate and technical accounting. Earlier in her career, Ms. Kumar was in the assurance services at Ernst and Young. Ms. Kumar earned an M.S in Accounting and Taxation from the University of Hartford. She is a certified public accountant.
- Renee Ryan
-
Renee Ryan，2013年起，担任本公司董事。自2019年8月以来，Ryan女士一直担任医疗技术公司Cala Health，Inc.的首席执行官。2011年至2019年8月，Ryan女士担任强生公司旗下风险投资部门强生公司Development Corp.的投资Vice President。Ryan从2008年到2011年担任Robert W.Baird&Co.（一家私募股权公司和金融服务公司）总经理。
Renee Ryan has served as a member of board of directors since 2013. Since August 2019 Ms. Ryan has served as Chief Executive Officer at Cala Health, Inc., a medical technology company. From 2011 to August 2019 Ms. Ryan served as Vice President, Investments, at Johnson & Johnson Development Corp., the venture investing arm of Johnson & Johnson. From 2008 to 2011 Ms. Ryan served as Managing Director at Robert W. Baird & Co., a private equity firm and financial services company. - Renee Ryan，2013年起，担任本公司董事。自2019年8月以来，Ryan女士一直担任医疗技术公司Cala Health，Inc.的首席执行官。2011年至2019年8月，Ryan女士担任强生公司旗下风险投资部门强生公司Development Corp.的投资Vice President。Ryan从2008年到2011年担任Robert W.Baird&Co.（一家私募股权公司和金融服务公司）总经理。
- Renee Ryan has served as a member of board of directors since 2013. Since August 2019 Ms. Ryan has served as Chief Executive Officer at Cala Health, Inc., a medical technology company. From 2011 to August 2019 Ms. Ryan served as Vice President, Investments, at Johnson & Johnson Development Corp., the venture investing arm of Johnson & Johnson. From 2008 to 2011 Ms. Ryan served as Managing Director at Robert W. Baird & Co., a private equity firm and financial services company.
- Joel Becker
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Richard Scott Huennekens
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Lisa Andrade
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Uri Geiger
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Joseph Lacob
-
Joseph Lacob，自2010年起，担任NBA最成功球队之一金州勇士队的州长、联席执行主席、首席执行官，以及金州WNBA球队。在他的带领下，勇士队不仅在球场上取得了重大成功，包括多个NBA总冠军，还通过他们在球迷参与和球队管理方面的创新方式，成为了现代体育球队的典范。在加盟勇士队之前，约瑟夫曾于1987年至2010年在领先的风险投资公司Kleiner Perkins Caufield & Byers担任合伙人。他在风险投资方面的经验为他在业务发展和投资战略方面提供了坚实的基础，特别是在技术和医疗保健领域。Joseph还曾在Cetus Corporation担任过多个职位，该公司现在是Chiron Corporation的一部分，专门从事生物技术。通过在健康维护组织FHP国际公司和知名咨询公司博思艾伦汉密尔顿公司任职，他获得了更多经验。除了在勇士队担任领导职务外，约瑟夫还在多个组织的董事会任职，其中包括自1997年以来一直担任董事会成员的NeuroPace公司，此前他曾于2004年至2012年在奥西珍医疗，Inc.任职。他拥有加州大学欧文分校生物科学理学学士学位、加州大学洛杉矶分校公共卫生硕士学位和斯坦福大学硕士学位。
Joseph Lacob,Since 2010, he has served as the Governor, Co-Executive Chairman, and Chief Executive Officer of the Golden State Warriors, one of the most successful teams in the NBA, as well as the Golden State WNBA team. Under his leadership, the Warriors have not only achieved significant successes on the court, including multiple NBA championships, but have also become a model for modern sports franchises through their innovative approach to fan engagement and team management. Prior to joining the Warriors, Joseph was a partner at Kleiner Perkins Caufield & Byers, a leading venture capital firm, from 1987 to 2010. His experience in venture capital provided him with a strong foundation in business development and investment strategies, particularly in the technology and healthcare sectors.Joseph also held various positions at Cetus Corporation, which is now part of Chiron Corporation, specializing in biotechnology. He gained additional experience through roles at FHP International, a health maintenance organization, and Booz Allen & Hamilton, a well-known consulting firm.In addition to his leadership with the Warriors, Joseph serves on the boards of several organizations, including NeuroPace, Inc., where he has been a board member since 1997, and he was previously involved with Orexigen Therapeutics, Inc. from 2004 to 2012.He holds a Bachelor of Science degree in Biological Sciences from the University of California at Irvine, a Master's in Public Health from the University of California at Los Angeles, and an MBA from Stanford University. - Joseph Lacob，自2010年起，担任NBA最成功球队之一金州勇士队的州长、联席执行主席、首席执行官，以及金州WNBA球队。在他的带领下，勇士队不仅在球场上取得了重大成功，包括多个NBA总冠军，还通过他们在球迷参与和球队管理方面的创新方式，成为了现代体育球队的典范。在加盟勇士队之前，约瑟夫曾于1987年至2010年在领先的风险投资公司Kleiner Perkins Caufield & Byers担任合伙人。他在风险投资方面的经验为他在业务发展和投资战略方面提供了坚实的基础，特别是在技术和医疗保健领域。Joseph还曾在Cetus Corporation担任过多个职位，该公司现在是Chiron Corporation的一部分，专门从事生物技术。通过在健康维护组织FHP国际公司和知名咨询公司博思艾伦汉密尔顿公司任职，他获得了更多经验。除了在勇士队担任领导职务外，约瑟夫还在多个组织的董事会任职，其中包括自1997年以来一直担任董事会成员的NeuroPace公司，此前他曾于2004年至2012年在奥西珍医疗，Inc.任职。他拥有加州大学欧文分校生物科学理学学士学位、加州大学洛杉矶分校公共卫生硕士学位和斯坦福大学硕士学位。
- Joseph Lacob,Since 2010, he has served as the Governor, Co-Executive Chairman, and Chief Executive Officer of the Golden State Warriors, one of the most successful teams in the NBA, as well as the Golden State WNBA team. Under his leadership, the Warriors have not only achieved significant successes on the court, including multiple NBA championships, but have also become a model for modern sports franchises through their innovative approach to fan engagement and team management. Prior to joining the Warriors, Joseph was a partner at Kleiner Perkins Caufield & Byers, a leading venture capital firm, from 1987 to 2010. His experience in venture capital provided him with a strong foundation in business development and investment strategies, particularly in the technology and healthcare sectors.Joseph also held various positions at Cetus Corporation, which is now part of Chiron Corporation, specializing in biotechnology. He gained additional experience through roles at FHP International, a health maintenance organization, and Booz Allen & Hamilton, a well-known consulting firm.In addition to his leadership with the Warriors, Joseph serves on the boards of several organizations, including NeuroPace, Inc., where he has been a board member since 1997, and he was previously involved with Orexigen Therapeutics, Inc. from 2004 to 2012.He holds a Bachelor of Science degree in Biological Sciences from the University of California at Irvine, a Master's in Public Health from the University of California at Los Angeles, and an MBA from Stanford University.
高管简历
中英对照 | 中文 | 英文- Martha Morrell
Martha Morrell自2004年以来担任我们的首席医疗官。Morrell博士还从2004年开始担任斯坦福大学（Stanford University）的神经学临床教授。Morrell博士之前从1998年到2004年担任哥伦比亚大学临床神经学Caitlin Tynan Doyle教授和纽约长老会医院哥伦比亚综合癫痫中心主任。在此之前，Morrell博士从1990年到1998年在斯坦福大学医学院（Stanford University School of Medicine）的教员和斯坦福综合癫痫中心（Stanford Comprehensive癫痫中心）的主任任职。Morrell博士在巴纳德学院（Barnard College）获得学士学位，在斯坦福大学医学院（Stanford University School of Medicine）获得硕士学位。
Martha Morrell has served as Chief Medical Officer since 2004. Dr. Morrell has also served as a Clinical Professor of Neurology at Stanford University since 2004. Dr. Morrell previously served as the Caitlin Tynan Doyle Professor of Clinical Neurology at Columbia University and Director of the Columbia Comprehensive Epilepsy Center at New York Presbyterian Hospital from 1998 to 2004. Prior to that, Dr. Morrell served on the faculty of the Stanford University School of Medicine and as the Director of the Stanford Comprehensive Epilepsy Center from 1990 to 1998. Dr. Morrell earned a B.A. from Barnard College and an M.D. from the Stanford University School of Medicine.- Martha Morrell自2004年以来担任我们的首席医疗官。Morrell博士还从2004年开始担任斯坦福大学（Stanford University）的神经学临床教授。Morrell博士之前从1998年到2004年担任哥伦比亚大学临床神经学Caitlin Tynan Doyle教授和纽约长老会医院哥伦比亚综合癫痫中心主任。在此之前，Morrell博士从1990年到1998年在斯坦福大学医学院（Stanford University School of Medicine）的教员和斯坦福综合癫痫中心（Stanford Comprehensive癫痫中心）的主任任职。Morrell博士在巴纳德学院（Barnard College）获得学士学位，在斯坦福大学医学院（Stanford University School of Medicine）获得硕士学位。
- Martha Morrell has served as Chief Medical Officer since 2004. Dr. Morrell has also served as a Clinical Professor of Neurology at Stanford University since 2004. Dr. Morrell previously served as the Caitlin Tynan Doyle Professor of Clinical Neurology at Columbia University and Director of the Columbia Comprehensive Epilepsy Center at New York Presbyterian Hospital from 1998 to 2004. Prior to that, Dr. Morrell served on the faculty of the Stanford University School of Medicine and as the Director of the Stanford Comprehensive Epilepsy Center from 1990 to 1998. Dr. Morrell earned a B.A. from Barnard College and an M.D. from the Stanford University School of Medicine.
- Joel Becker
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Patrick F. Williams
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介